BPC-157 side effects: what the data shows

BPC-157 has no approved regulatory label, no boxed warnings, and no post-marketing surveillance data, because it has never been approved as a medicine by the FDA, the EMA, or any other regulatory authority we track^[1]. That means the answer to "what are the side effects?" is shorter and less reassuring than most readers expect: we do not have the data that would normally generate such a list.

What the preclinical safety studies found

The most systematic safety evaluation to date is a 2020 preclinical toxicology package by Xu et al., published in Regulatory Toxicology and Pharmacology. It tested BPC-157 in mice, rats, rabbits, and dogs across single-dose toxicity, repeated-dose toxicity, local tolerance, genotoxicity, and embryo-fetal toxicity protocols. The authors reported that BPC-157 "was well tolerated and did not cause any serious toxicity" across all species tested^[2]. In dogs receiving repeated doses, the only finding was a transient decrease in creatinine at 2 mg/kg, which resolved after two weeks of withdrawal. Local injection-site irritation was described as mild. No genotoxicity or embryo-fetal toxicity was observed.

An earlier review by Sikiric et al. (2020) stated that no LD-1 (the lowest dose expected to kill one animal in a test group) was achieved in any study, and reported "no adverse effects in clinical trials," though the clinical trial data referenced has never been published in a peer-reviewed journal with full adverse-event tables.

The abandoned Phase I trial

The only registered human safety trial is NCT02637284 ("PCO-02, Safety and Pharmacokinetics Trial"), a Phase I study in 42 healthy volunteers aged 18 to 35 at Hospital Angeles in Tijuana. It tested oral BPC-157 tablets at single doses of 1, 3, or 6 tablets (Phase 1a) and repeated dosing of 3 tablets three times daily for two weeks (Phase 1b). The trial was registered in December 2015 and cancelled in 2016^[3]. No results were ever published. That means the only controlled human safety data that might exist for BPC-157 is locked in an abandoned trial with no public output.

Theoretical safety concerns from the mechanism

A 2025 literature review by Jozwiak et al. in Pharmaceuticals identified three mechanism-based concerns that have not been tested in humans but follow from what BPC-157 does in animal models^[4].

First, angiogenesis risk. BPC-157 promotes new blood-vessel growth, which is the basis of its proposed tissue-repair benefit. But pro-angiogenic compounds can theoretically support tumour vascularisation. The review noted that administration of BPC-157 to mice with implanted cancer cells "did not result in a spectacular reduction in tumour size," raising the question of whether BPC-157 could feed undetected malignancies rather than fight them.

Second, excessive nitric-oxide stimulation. BPC-157 modulates the nitric-oxide system. At high levels, nitric oxide can inhibit key enzymes (including cytochrome P450), contribute to iron accumulation in neural tissue, and generate peroxynitrite, a potent oxidant that damages DNA and proteins.

Third, metabolite effects. One metabolite of the peptide is proline, which when processed by proline oxidase can produce superoxide and deplete intracellular proline stores, contributing to oxidative stress.

None of these three risks has been observed in a human subject. They are extrapolations from pharmacology, not clinical findings. But they are the kind of signals that a Phase II or Phase III trial would be designed to monitor, and no such trial exists.

What self-reports and case series describe

Outside the formal literature, the most commonly reported complaint from people who have used grey-market BPC-157 is injection-site pain or irritation, consistent with the "mild local irritation" noted in the Xu preclinical package. Online forums and clinic case series also mention transient nausea, dizziness, and headache, but these reports lack controls, dose standardisation, product-identity verification, and the kind of systematic collection that would make them usable as safety data.

The US Department of Defense's Operation Supplement Safety programme warns service members that BPC-157 is "an unapproved drug" and that "no one knows if there is a safe dose"^[5]. USADA frames it similarly: because BPC-157 has not been studied in humans in any controlled way, there is no basis for claiming a known safety profile^[1].

What this page is not

This is not a finding that BPC-157 is dangerous. It is a finding that the safety question remains open. The rodent toxicology is reassuring as far as rodent toxicology goes, but rodent safety is not human safety, and the gap between the two has not been bridged by any published human trial. Anyone considering BPC-157 should discuss it with a clinician who knows their medical history. For the per-country regulatory picture, see the BPC-157 regulation pages.